Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 18 Aug 2021
Sutro Biopharma announces STRO-002 FDA fast track designation for patients with advanced ovarian cancer
18 August 2021 - Sutro Biopharma today announced that the U.S. FDA has granted fast track designation for STRO-002, a folate ...
Posted by Michael Wonder on 18 Aug 2021
Joint statement from HHS public health and medical experts on COVID-19 booster shots
18 August 2021 - Today, public health and medical experts from the U.S. Department of Health and Human Services released the ...
Posted by Michael Wonder on 18 Aug 2021
Update on Actemra (tocilizumab) supply in the U.S.
16 August 2021 - The unprecedented surge in worldwide demand and supply constraints driven by Delta variant spikes in much ...
Posted by Michael Wonder on 18 Aug 2021
AmoyDx Pan lung cancer PCR panel receives MHLW approval as companion diagnostic for Tepmetko (tepotinib)
17 August 2021 - Riken Genesis, Amoy Diagnostics and Precision Medicine Asia today announced that the Ministry of Health, Labour ...
Posted by Michael Wonder on 18 Aug 2021
Abiraterone acetate for treating newly diagnosed high-risk hormone sensitive metastatic prostate cancer
18 August 2021 - NICE has published final guidance on the use of Zytiga in newly diagnosed patients following an ...
Posted by Michael Wonder on 18 Aug 2021
COVID-19 vaccines additional doses: codes & payment
16 August 2021 - The FDA amended the emergency use authorisations for both the Pfizer BioNTech COVID-19 vaccine and the ...
Posted by Michael Wonder on 18 Aug 2021
Moderna COVID-19 vaccine approved by MHRA in 12-17 year olds
17 August 2021 - The UK regulator has confirmed the vaccine is safe and effective in this age group. ...
Posted by Michael Wonder on 18 Aug 2021
BeiGene and EUSA Pharma announce China NMPA approval of Qarziba (dinutuximab beta) for patients with high risk neuroblastoma
17 August 2021 - BeiGene and EUSA Pharma today announced that the China National Medical Products Administration has granted Qarziba (dinutuximab ...
Posted by Michael Wonder on 18 Aug 2021
Pharmaceutical companies should pay for raiding nature's medicine cabinet
11 August 2021 - In 2019, the pharmaceutical industry profited from US$1·2 trillion of global spending on medicines. Most of this ...
Posted by Michael Wonder on 17 Aug 2021
Tempus submits PMA application to the FDA for its xT-Onco assay
17 August 2021 - Tempus today announced the submission of a premarket approval application for its proprietary broad-panel DNA sequencing ...
Posted by Michael Wonder on 17 Aug 2021
Novartis secures new approval in China for Cosentyx (secukinumab) in paediatric psoriasis
17 August 2021 - China NMPA approval reinforces that Cosentyx (secukinumab) is safe and effective for children and adults with psoriasis. ...
Posted by Michael Wonder on 17 Aug 2021
Will Government further expand reimbursement for rare leukaemia drugs?
17 August 2021 - As the Government has gradually increased reimbursement for combination drugs treating chronic lymphocytic leukaemia, patients’ hopes ...
Posted by Michael Wonder on 17 Aug 2021
EMA validates Bristol Myers Squibb’s applications for Opdivo (nivolumab) and Yervoy (ipilimumab) and Opdivo and chemotherapy as first-line treatments for unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma
17 August 2021 - Applications based on positive results from the Phase 3 CheckMate-648 trial, in which both Opdivo-based combinations demonstrated ...
Posted by Michael Wonder on 17 Aug 2021
ICER publishes final evidence report and policy recommendations on therapies for atopic dermatitis
17 August 2021 - Given uncertainty about safety data on oral JAK inhibitors for other indications, a narrow majority of the ...
Posted by Michael Wonder on 17 Aug 2021
Agios announces FDA acceptance and priority review of new drug application for mitapivat for treatment of adults with pyruvate kinase deficiency
17 August 2021 - PDUFA date set for 17 February 2022. ...